ArticleReproductive sciences (Thousand Oaks, Calif.)2026
CA125 Outperforms HE4 and CA19-9 as a Serum Biomarker for Preoperative Diagnosis of Ovarian Endometriomas: A Retrospective Cohort Study.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate pre-operative discrimination between ovarian endometriomas (EMs) and other benign ovarian tumors is crucial for surgical planning and fertility counseling. This study aimed to evaluate the diagnostic performance of serum CA125, CA19-9, and HE4 in differentiating endometriomas from non-endometriotic benign ovarian cysts. This retrospective cohort study included 654 patients with histologically confirmed benign ovarian cysts (343 endometriomas and 311 other benign ovarian tumors) from January 2024 to March 2025. Serum CA125, CA19-9, and HE4 levels were compared between groups. Receiver operating characteristic (ROC) analysis was performed to assess diagnostic accuracy, with stratified analyses by age, dysmenorrhea, cyst laterality, and parity. Patients with endometriomas had significantly elevated CA125 (median: 56.40 vs. 17.30 U/mL, P<0.001) and HE4 (31.50 vs. 14.94 pmol/L, P<0.001), whereas CA19-9 showed no significant difference. ROC analysis revealed that CA125 had excellent diagnostic performance (AUC=0.895; sensitivity=85.7% (95% CI: 81.6-89.2%); specificity=80.6% (95% CI: 75.8-84.9%) at cutoff=27.45 U/mL), consistently superior across all subgroups. HE4 demonstrated moderate utility (AUC=0.683), while CA19-9 lacked discriminatory value. Serum CA125 reliably distinguishes endometriomas from other benign ovarian tumors across diverse clinical scenarios. CA125 should be routinely integrated as a biochemical adjunct to ultrasonography, whereas HE4 and CA19-9 have limited clinical utility in this context. The retrospective design of this study should be considered when interpreting the findings.
Indexed as
Identifiers
42115575What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.